UFP Technologies Inc. (UFPT) outlined a growth plan centered on scaling its outsourced medical device manufacturing operations during a presentation at the 17th Annual Midwest IDEAS Conference on Wednesday.
The Newburyport, Massachusetts-based company, which reported trailing twelve-month revenue of $631.6 million and a market capitalization of approximately $2.36 billion, aims for a blended annual growth rate of 12% to 18% over the next three to five years. UFP’s strategy focuses on expanding its global manufacturing footprint and pursuing acquisitions to capture share in the fragmented $100 billion outsourced medical device market, which is growing at roughly 10% annually.
Chief Executive Officer Mitch Roch described UFP’s role as an enabler for the broader medical device industry, stating the company provides foundational components rather than finished devices. "We don’t make the devices you’ve heard of. We help make them work," Roch said. He highlighted the company’s less than 1% share of the $100 billion outsourced market as an opportunity for expansion, comparing UFP’s position to "the picks and shovels for the medical device industry."
UFP operates six manufacturing sites across the U.S., Puerto Rico, Ireland, Mexico, Costa Rica, and the Dominican Republic, employing more than 5,000 team members. The company targets gross margins of 28% to 31% and adjusted operating margins of 17% to 20% in the medium term. Financial metrics provided by InvestingPro show a trailing twelve-month diluted earnings per share of $9.25, a gross profit margin of 28.5%, a return on equity of 17%, and a year-to-date stock return of 37%.
The company’s M&A pipeline includes five to ten active opportunities under review, with potential targets ranging from $5 million to $30 million in EBITDA. Recent acquisitions, including DAS Medical, AJR, AQF Medical, and others, have expanded UFP’s presence in robotic-assisted surgery, patient handling, cardiovascular, and wound care segments. The Dominican Republic operations, which include two independent businesses, continue to receive investment and have grown since their acquisition.
Roch also emphasized UFP’s long-term customer relationships, noting the company typically supports programs for a decade or more. "We get in early, we earn the program, we ride with it for the life of the device," he said. Chief Financial Officer Ron Lataille added that inventory growth is demand-driven, reflecting future order activity rather than speculative buildup.
UFP’s primary market exposure includes robotic-assisted surgery, patient beds and handling, cardiovascular, infection control, orthopedics and spine, and wound care, with secondary exposure in endoscopy, imaging, and other segments. The company’s stock has gained 41% over the past six months, according to InvestingPro data.
